Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines

Pediatrics

Volumn 123, Issue 2, 2009, Pages 475-482

  Tozzi, Alberto Eugenio ^a   Bisiacchi, Patrizia ^b   Tarantino, Vincenza ^b   De Mei, Barbara ^c   D'Elia, Lidia ^c   Chiarotti, Flavia ^c   Salmaso, Stefania ^c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c National Health Institute   (Italy)

Author keywords

Child; Controlled trial; Developmental disabilities; Ethylmercury compounds; Immunization; Randomized; Thimerosal

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ETHYLMERCURY DERIVATIVE; PERTUSSIS VACCINE; THIOMERSAL; PRESERVATIVE; VACCINE;

ARTICLE; ATTENTION; CONTROLLED STUDY; DEPTH PERCEPTION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNIZATION; INFANT; LANGUAGE ABILITY; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PERTUSSIS; PRIORITY JOURNAL; SCORING SYSTEM; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEVELOPMENTAL DISORDER; RANDOMIZED CONTROLLED TRIAL; TIME;

CHILD; DEVELOPMENTAL DISABILITIES; FEMALE; HUMANS; INFANT; MALE; NEUROPSYCHOLOGICAL TESTS; PRESERVATIVES, PHARMACEUTICAL; THIMEROSAL; TIME FACTORS; VACCINES;

EID: 61549103786     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0795     Document Type: Article

References (30)

1. Institute of Medicine. Immunization Safety Review: Thimerosal- Containing Vaccines and Neurodevelopmental Disorders. Washington, DC: National Academy Press; 2001
2. Geier DA, Geier MR. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of thimerosal from childhood vaccines. Med Sci Monit. 2006;12(6):CR231-CR239
3. Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimer- osal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003; 112(5):1039-1048
4. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics. 2004;114(3):584-591
5. Geier D, Geier MR. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis. Int J Toxicol. 2004;23(6):369-376
6. Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med. 2003;25(2):101-106
7. Heron J, Golding J; ALSPAC Study Team. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. Pediatrics. 2004;114(3):577-583
8. Fombonne E, Zakarian R, Bennett A, Meng L, McLean- Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1). Available at: www.pediatrics.org/cgi/content/full/118/1/e139
9. Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007;357(13):1281-1292
10. Schechter R, Grether JK. Continuing increases in autism reported to California's developmental service system. Arch Gen Psychiatry. 2008;65(1):19-24
11. McCormick M, Bayer R, Berg A. Report of the Institute of Medicine: Immunization Safety Review: Vaccines and Autism. Washington, DC: National Academy Press; 2004
12. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal- containing vaccines and autistic spectrum disorders: a critical review of published original data. Pediatrics. 2004;114(3):793-804
13. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics. 2001;107(5):1147-1154
14. Pichichero ME, Gentile A, Giglio N, et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics. 2008;121(2). Available at: www.pediatrics.org/cgi/content/full/121/2/e208
15. European Agency for the Evaluation of Medicinal Products. EMEA public statement on thiomersal containing medicinal products, July 8, 1999. Available at: www.emea.europa.eu/pdfs/human/press/pus/2096299EN.pdf. Accessed December 12, 2008
16. Centers for Disease Control and Prevention. Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep. 1999;48(26):563-565
17. Centers for Disease Control and Prevention. Recommendations regarding the use of vaccines that contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep. 1999;48(43):996-998
18. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334(6):341-348
19. Salmaso S, Mastrantonio P, Wassilak SG, et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine. 1998;16(13):1270-1275
20. Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001;108(5). Available at: www.pediatrics.org/cgi/content/full/108/5/e81
21. Grandjean P, Budtz-Jorgensen E, White RF, et al. Methylmer- cury exposure biomarkers as indicators of neurotoxicity in children aged 7 years. Am J Epidemiol. 1999;150(3):301-305
22. Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test-Children Version. New York, NY: Psychological Corp;1994
23. Wechsler D. WISC-R: Scala di Intelligenza Wechsler per Bambini Riveduta: Manuale [WISC-R: Wechsler Intelligence Scale for Children-Revised: Manual; in Italian]. Florence, Italy: Organizzazioni Speciali; 1998
24. Conners CK; Multi-Health Systems Staff. Conners' Continuous Performance Test. Toronto, Canada: Multi-Health Systems; 2000
25. Bisiacchi PS, Cendron M, Gugliotta M, Tressoldi P, Vio C. Batteria di Valutazione Neuropsicologica per l'Età Evolutiva [Battery for Neuropsychological Evaluation in Childhood; in Italian]. Trent, Italy: Erickson; 2005
26. Kaplan E, Goodglas H, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea & Febinger; 1983
27. Nussbaum NL, Bigler ED. Halstead-Reitan neuropsychological test batteries for children. In: Reynolds C, ed. Handbook of Clinical Child Neuropsychology. 2nd ed. New York, NY: Plenum Press; 1997
28. Tressoldi PE, Cornoldi C. Batteria per la Valutazione Della Scrittura e Della Competenza Ortografica Nella Scuola Dell'Obbligo [Battery for the Evaluation of Writing and Spelling Competence in Elementary and Junior High School; in Italian]. Florence, Italy: Organizzazioni Speciali; 1991
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994
30. Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ Health Perspect. 2005;113(8):1015-1021